Kemble George 4
4 · Sagimet Biosciences Inc. · Filed Nov 21, 2025
Insider Transaction Report
Form 4
Kemble George
DirectorExecutive Chairman
Transactions
- Sale
Series A Common Stock
2025-11-20$7.69/sh−37,688$289,979→ 81,005 total
Footnotes (2)
- [F1]These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.27 to $8.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.